Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer

  • Technology appraisal guidance
  • TA660
  • Published: 

History

Documents created during the development process.

Expected publication

Final draft guidance: 1

Invitation to participate

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators